|Organization:||Unicamp Innovation Agency, São Paulo, BR|
|I.P. Brief:||The technology involves the use of an active peptide against Eimeria sporozoites, but without any activity against a number of avian, mammalian or bacterial cells.|
|Summary of I.P.:||The conventional anticoccidial drug therapy is getting progressively lower, because of the acquired resistance by the parasite. Other problem is the crescent market restriction to products originated from animals that were treated with chemicals. Nowadays, there isn’t any new drug available as an alternative to control avian coccidiosis that solves the above problems.
The present technology involves the use of an active peptide, selected from huge peptide libraries using an innovative method. The final result is a peptide active against Eimeria sporozoites, but without any activity against a number of avian, mammalian or bacterial cells. The peptide also showed some activity against filamentous fungi and yeast. The activity of this peptide involves permeabilization of the parasite membrane impairing cell functions. There is also evidence that the peptide enters into the cytoplasm interfering with other important cell functions.
The use of peptides imposes a difficulty to the development of parasite resistance. Other advantage of a new peptide based therapy would be the complete absence of drug residues in birds meat or eggs.
The animal pharma industry is the target industry for the product derived from this technology.|
|Patent:||US20030148397; EP1262556; PI0202064-5|
|Keywords:||Avian coccidiosis, anticoccidial peptide; Eimeria.|
|Primary Industry:||Pharma & Biotech|
|Specific Market:||Avian coccidiosis therapy|
|Market Size:||The market for avian coccidiosis is around US$ 1 billion dollars per year all over the world.|
|State of the Art:||Nowadays, the avian coccidiosis is fought with a anticoccidial drug therapy, that is added in the avian ration. However, the parasite has acquired resistance for these drugs. Also, such drugs can leave residues in the birds meat or eggs.|
|Competition:||Not detected. |
|Figures of Merit:||- It is not a drug therapy;
- There is no activity against a number of avian, mammalian or bacterial cells;
- The technology difficults the development of parasite resistance against the peptide;
- Complete absence of drug residues in birds meat or eggs;
- It is possible to consider drug design. |
|Tech. Obstacles:||- The research is still in a development stage and there are many possible strategies to explore the peptide function in order to obtain novel product against avian coccidiosis.
- Conduce in vivo tests;
- If drug design is considered: Design a chemical compound that resembles peptide structure and activity.|
|Market Obstacles:||- Present stage: tests in vitro
- To make tests in vivo;
- Develop an economically viable method of production of peptide
- Scale up.
- Develop an economically viable synthesis method of the drug.|
|Patent Landscape:||018050058393 (Brazil); PI0405361-3 (Brazil); PI9805166-0 (Brazil)|
|Publications:||- Da Silva Jr., A, et all. Avian anticoccidial activity of a novel membrane-interactive peptide selected from phage display libraries. Molecular & Biochemical Parasitology, Elsevier Science: 2002.
- NMR structure of PW2 bound to SDS micelles. A tryptophan-rich anticoccidial peptide selected from phage display libraries. J Biol Chem. 2002 Sep 27;277(39):36351-6.|
|Research Team:||Arnaldo da Silva Junior
- Doctor in Biotechnology
- Research leader
- 10 years of research experience |